Aytu BioPharma (AYTU) Balance Sheet: Assets & Liabilities

Aytu BioPharma (AYTU) Balance Sheet

As of Jun 30, 2026 (end of fiscal 2026), Aytu BioPharma reported total assets of $105.01M and total liabilities of $69.73M. Shareholders' equity was $35.27M, up 86.0% from $18.97M a year earlier. Total debt stood at $18.11M against $26.31M in cash and short-term investments, a net cash position of $8.20M. That puts debt-to-equity at 0.51, compared with 1.21 a year earlier.

Aytu BioPharma Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Aytu BioPharma, Inc. (AYTU) - Annual data in millions USD
Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Jun 2026	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Sep 2020	Jun 2019	Jun 2018	Jun 2017
Current Assets
Cash and Cash Equivalents	26.31	30.95	20.01	22.99	19.36	49.65	48.08	11.04	7.01	0.80
Cash & Short-Term Investments	26.31	30.95	20.01	22.99	19.36	49.65	48.08	11.04	7.01	0.80
Accounts Receivable	22.78	31.16	23.53	28.94	21.71	28.18	5.63	1.74	0.58	0.53
Inventory	6.86	11.43	12.14	8.51	10.85	16.34	10.00	1.44	1.34	1.31
Other Current Assets	5.81	5.64	5.10	7.16	8.01	11.07	11.71	1.21	0.54	0.39
Total Current Assets	61.76	79.18	61.89	71.08	59.93	105.23	75.42	15.43	9.47	3.03
Non-Current Assets
Property, Plant & Equipment (Net)	1.24	1.59	1.52	3.87	6.30	8.70	0.89	0.20	0.22	0.65
Long-Term Investments	0.00	0.00	0.00	0.00	0.00	-10.91	0.00	0.00	0.00	0.00
Goodwill	0.00	0.00	0.00	0.00	0.00	65.80	28.09	0.00	0.00	0.24
Intangible Assets	41.40	42.20	52.45	57.44	70.63	85.46	48.86	19.08	11.37	11.08
Other Non-Current Assets	0.60	1.20	2.23	2.55	0.77	0.47	0.03	0.00	0.00	0.00
Total Non-Current Assets	43.25	45.00	56.20	65.38	77.69	160.43	77.87	19.29	11.59	11.97
Total Assets	105.01	124.18	118.10	136.46	137.62	265.67	153.29	34.72	21.06	15.00
Current Liabilities
Accounts Payable	11.28	10.60	10.31	13.48	10.99	19.26	11.64	2.13	2.12	2.22
Short-Term Debt	8.15	11.06	4.25	1.56	3.81	25.54	1.28	0.00	0.00	0.00
Current Portion of Long-Term Debt	-	1.86	1.86	0.09	0.10	16.67	-	-	-	-
Accrued Liabilities	27.56	28.22	28.71	46.80	44.19	57.23	-	-	-	-
Deferred Revenue	0.00	0.00	0.00	0.00	0.00	57.23	0.34	0.00	0.00	0.00
Other Current Liabilities	35.22	41.41	9.52	7.09	5.36	7.41	15.33	3.24	1.28	1.39
Total Current Liabilities	54.66	63.06	62.23	69.02	64.44	109.44	28.76	5.37	3.39	3.61
Non-Current Liabilities
Long-Term Debt	9.95	11.88	10.88	14.71	14.28	5.43	0.73	0.00	0.00	0.00
Deferred Tax Liabilities	0.00	0.00	0.76	1.38	0.00	11.15	0.00	0.00	0.00	0.00
Other Non-Current Liabilities	5.12	30.27	4.53	13.38	14.59	13.23	28.79	22.26	4.24	7.39
Total Non-Current Liabilities	15.07	42.15	28.15	28.09	28.87	18.66	29.52	22.26	4.24	7.39
Total Liabilities	69.73	105.21	90.38	97.11	93.32	128.10	58.28	27.63	7.64	11.00
Stockholders' Equity
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Retained Earnings	-347.79	-333.54	-319.97	-304.13	-287.08	-178.30	-120.01	-106.39	-79.26	-69.07
Accumulated Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.25
Additional Paid-in Capital	383.06	352.50	347.69	343.49	331.39	315.86	215.02	113.48	92.68	73.07
Shares Outstanding	10.73	8.98	5.97	5.52	1.93	-	-	-	-	-
Total Stockholders' Equity	35.27	18.97	27.72	39.36	44.31	137.57	95.02	7.09	13.42	4.00
Total Liabilities & Equity	105.01	124.18	118.10	136.46	137.62	265.67	153.29	34.72	21.06	15.00

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Aytu BioPharma Balance Sheet

How much debt does Aytu BioPharma have?

Aytu BioPharma had total debt of $18.11M as of Jun 30, 2026, against $26.31M in cash and short-term investments. Its debt-to-equity ratio was 0.51. Total debt was $22.94M a year earlier.

What are Aytu BioPharma's total assets?

Aytu BioPharma reported total assets of $105.01M as of Jun 30, 2026, down 15.4% from $124.18M a year earlier. Total liabilities were $69.73M.

What is Aytu BioPharma's shareholders' equity?

Aytu BioPharma's shareholders' equity was $35.27M as of Jun 30, 2026, or about $3.29 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition